Key result
Kanglexin (KLX) reduced blood lipids, hepatic lipid accumulation, and body weight in high-fat diet-fed rats by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
Why the study?
Hyperlipidaemia is a major risk factor for cardiometabolic diseases, motivating the evaluation of the lipid-lowering effects and molecular mechanisms of a newly synthesized anthraquinone compound, Kanglexin.
Does Kanglexin reduce lipid accumulation in hyperlipidemic rat and cell models?
Does Kanglexin reduce lipid accumulation in hyperlipidemic rat and cell models?
Kanglexin, a novel anthraquinone compound, demonstrates lipid-lowering effects in hyperlipidemic models via activation of the AMPK/SREBP-2/PCSK9/LDLR signaling pathway.
Answers are grounded in this paper and cite their sources.
KLX lipid-lowering in HFD rats is hypothesis-generating; leaves open translation to human hyperlipidemia therapy.
Hyperlipidaemia is one of the major risk factors for atherosclerosis, coronary heart disease, stroke and diabetes. In the present study, we synthesized a new anthraquinone compound, 1,8-dihydroxy-3-succinic acid monoethyl ester-6-methylanthraquinone, and named it Kanglexin (KLX). The aim of this study was to evaluate whether KLX has a lipid-lowering effect and to explore the potential molecular mechanism. In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg−1·d−1) or atorvastatin calcium (AT, 10 mg kg−1·d−1) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphorylating adenosine monophosphate-activated protein kinase (AMPK) and the downstream sterol regulatory element binding protein 2 (SREBP-2)/proprotein convertase subtilisin/kexin type 9 (PCSK9)/low-density lipoprotein receptor (LDLR) signalling pathway in the HFD rats and OA-treated HepG2 cells. The effects of KLX on the AMPK/SREBP-2/PCSK9/LDLR signalling pathway were abolished when AMPK was inhibited by compound C (a specific AMPK inhibitor) in HepG2 cells. In summary, KLX has an efficient lipid-lowering effect mediated by activation of the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Our findings may provide new insight into and evidence for the discovery of a new lipid-lowering drug for the prevention and treatment of hyperlipidaemia, fatty liver, and cardiovascular disease in the clinic.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied Hyperlipidaemia. Kanglexin (KLX) vs. Atorvastatin calcium (10 mg kg−1·d−1) and untreated controls was evaluated on Blood lipids, hepatic lipid accumulation, body weight, and liver weight/body weight ratio. Kanglexin (KLX) reduced blood lipids, hepatic lipid accumulation, and body weight in high-fat diet-fed rats by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: